

# Brian Olshansky, Fhrs

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5288424/publications.pdf>

Version: 2024-02-01

360  
papers

18,848  
citations

11608

70  
h-index

13727

129  
g-index

388  
all docs

388  
docs citations

388  
times ranked

12972  
citing authors

#	ARTICLE	IF	CITATIONS
1	Importance of resting heart rate. Trends in Cardiovascular Medicine, 2023, 33, 502-515.	2.3	17
2	Heart rate score and outcomes in ICD patients: insights from the prospective randomized INTRINSIC RV trial. Journal of Interventional Cardiac Electrophysiology, 2022, 64, 87-93.	0.6	5
3	Stimulant Drugs of Abuse and Cardiac Arrhythmias. Circulation: Arrhythmia and Electrophysiology, 2022, 15, CIRCEP121010273.	2.1	23
4	Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIAâ€AF Phase III Registry. Journal of the American Heart Association, 2022, 11, e023907.	1.6	12
5	Orthostatic Hypotension: Management of a Complex, But Common, Medical Problem. Circulation: Arrhythmia and Electrophysiology, 2022, 15, CIRCEP121010573.	2.1	25
6	Association Between Atrial Fibrillation and Occupational Exposure in Firefighters Based on Selfâ€Reported Survey Data. Journal of the American Heart Association, 2022, 11, e022543.	1.6	2
7	Drug Interactions Affecting Antiarrhythmic Drug Use. Circulation: Arrhythmia and Electrophysiology, 2022, 15, 101161CIRCEP121007955.	2.1	6
8	The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an <scp>individual patient data metaâ€analysis</scp> of <scp>COMPANION</scp> and <scp>CAREâ€CHF</scp>. European Journal of Heart Failure, 2022, 24, 1080-1090.	2.9	11
9	Drug Interactions Affecting Oral Anticoagulant Use. Circulation: Arrhythmia and Electrophysiology, 2022, 15, .	2.1	13
10	Editorial commentary: The autonomic nervous system is our friend. Trends in Cardiovascular Medicine, 2021, 31, 303-304.	2.3	0
11	Is competitive atrial pacing a possible trigger for atrial fibrillation? Observations from the RATE registry. Heart Rhythm, 2021, 18, 3-9.	0.3	2
12	REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e61-e63.	1.4	23
13	Peripheral Arterial Disease in Patients with Atrial Fibrillation: The AFFIRM Study. American Journal of Medicine, 2021, 134, 514-518.	0.6	18
14	Anticoagulant selection in relation to the SAME-TT2R2 score in patients with atrial fibrillation: The GLORIA-AF registry. Hellenic Journal of Cardiology, 2021, 62, 152-157.	0.4	2
15	Tilt testing remains a valuable asset. European Heart Journal, 2021, 42, 1654-1660.	1.0	50
16	Predictors of myocardial recovery in arrhythmiaâ€induced cardiomyopathy: A multicenter study. Journal of Cardiovascular Electrophysiology, 2021, 32, 1085-1092.	0.8	12
17	Implantable Cardioverter Defibrillator Lead Survival in Athletic Patients. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009344.	2.1	3
18	Omega-3 Fatty Acids Effect on Major Cardiovascular Events in Patients at High Cardiovascular Risk. JAMA - Journal of the American Medical Association, 2021, 325, 1332.	3.8	9

#	ARTICLE	IF	CITATIONS
19	Long-Haul Post-COVID-19 Symptoms Presenting as a Variant of Postural Orthostatic Tachycardia Syndrome. <i>JACC: Case Reports</i> , 2021, 3, 573-580.	0.3	141
20	Heart rate score, a measure related to chronotropic incompetence in pacemaker patients. <i>Heart Rhythm</i> 2021, 2, 124-131.	0.6	8
21	Disparities in atrial fibrillation management: Is race to blame?. <i>International Journal of Cardiology</i> , 2021, 331, 118-119.	0.8	1
22	Marijuana use disorder and arrhythmias: what were they smoking?. <i>Europace</i> , 2021, 23, 1155-1156.	0.7	0
23	Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2021, 144, e41-e55.	1.6	47
24	Managing Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction: A Scientific Statement From the American Heart Association. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, HAE0000000000000078.	2.1	54
25	Sinus node dysfunction - A well-defined entity?. <i>International Journal of Cardiology</i> , 2021, 335, 55-56.	0.8	1
26	Lower rate limit for pacing by cardiac resynchronization defibrillators: Should lower rate programming be reconsidered?. <i>Heart Rhythm</i> , 2021, 18, 2087-2093.	0.3	4
27	Outcomes and predictors of readmission after implantation of a percutaneous left atrial appendage occlusion device in the United States: A propensity score-matched analysis from The National Readmission Database. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 2961-2970.	0.8	4
28	Mast Cell Activation Disorder and Postural Orthostatic Tachycardia Syndrome: A Clinical Association. <i>Journal of the American Heart Association</i> , 2021, 10, e021002.	1.6	20
29	Underlying hemodynamic differences are associated with responses to tilt testing. <i>Scientific Reports</i> , 2021, 11, 17894.	1.6	7
30	Toward a Common Definition of Syncope in Children and Adults. <i>Pediatric Emergency Care</i> , 2021, 37, e66-e67.	0.5	2
31	Anthracycline-induced cardiomyopathy: Is there a new light at the end of the tunnel?. <i>Heart Rhythm</i> 2021, 2, 742-743.	0.6	0
32	Dabigatran Persistence and Outcomes Following Discontinuation in Atrial Fibrillation Patients from the GLORIA-AF Registry. <i>American Journal of Cardiology</i> , 2020, 125, 383-391.	0.7	19
33	REDUCE-IT USA. <i>Circulation</i> , 2020, 141, 367-375.	1.6	104
34	Editorial commentary: Vagal nerve stimulation for myocardial ischemia-reperfusion injury: Hope or Hype?. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 489-490.	2.3	2
35	Heart rate score predicts mortality independent of shocks in ICD and CRT-D patients. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2020, 58, 103-111.	0.6	0
36	Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the ASCD-HeFT. <i>Journal of the American College of Cardiology</i> , 2020, 76, 405-415.	1.2	43

#	ARTICLE	IF	CITATIONS
37	The electrocardiogram: are we at the dawn of a new era?. <i>European Heart Journal</i> , 2020, 41, 2000-2002.	1.0	2
38	Comprehensive Management With the ABC (Atrial Fibrillation Better Care) Pathway in Clinically Complex Patients With Atrial Fibrillation: A Post Hoc Ancillary Analysis From the AFFIRM Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e014932.	1.6	84
39	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. <i>Europace</i> , 2020, 22, 1147-1148.	0.7	62
40	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. <i>Journal of Arrhythmia</i> , 2020, 36, 553-607.	0.5	40
41	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. <i>Heart Rhythm</i> , 2020, 17, e269-e316.	0.3	15
42	TACH-ING AWAY: PERMANENT JUNCTIONAL RECIPROCATING TACHYCARDIA. <i>Journal of the American College of Cardiology</i> , 2020, 75, 3221.	1.2	0
43	Cardiovascular Safety Considerations in the Treatment of Neurogenic Orthostatic Hypotension. <i>American Journal of Cardiology</i> , 2020, 125, 1582-1593.	0.7	15
44	Guidance for cardiac electrophysiology during the COVID-19 pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association. <i>Heart Rhythm</i> , 2020, 17, e233-e241.	0.3	190
45	Postural Orthostatic Tachycardia Syndrome (POTS): A critical assessment. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 263-270.	1.6	58
46	Guidance for Cardiac Electrophysiology During the COVID-19 Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association. <i>Circulation</i> , 2020, 141, e823-e831.	1.6	122
47	Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. <i>European Heart Journal Supplements</i> , 2020, 22, J34-J48.	0.0	68
48	Pacing Therapies for Vasovagal Syncope. <i>Journal of Atrial Fibrillation</i> , 2020, 13, 2406.	0.5	5
49	Device Autonomic Regulation Therapy in Patients with Heart Failure and Reduced Ejection Fraction. <i>Journal of Atrial Fibrillation</i> , 2020, 13, 2409.	0.5	0
50	Syncope: Definition and Classification-Contrasting the American and European Guidelines. , 2020, , 3-16.		0
51	A 63-Year-Old Man with Atrial Fibrillation and Syncope. , 2020, , 67-68.		0
52	REDUCE-IT: accumulation of data across prespecified interim analyses to final results. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
53	Abstract 14500: Physical Activity in Individuals With the Long Qt Syndrome: Baseline Data From the Lifestyle and Exercise in Long Qt Study (live Lqts). <i>Circulation</i> , 2020, 142, .	1.6	0
54	Inappropriate sinus tachycardia. <i>Europace</i> , 2019, 21, 194-207.	0.7	50

#	ARTICLE	IF	CITATIONS
55	Electrolytes and the ECG Intervals. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3132-3134.	1.2	3
56	Neurohormones in Vasovagal Syncope: Are They Important?. <i>Journal of the American Heart Association</i> , 2019, 8, e013129.	1.6	6
57	Short-Term Outcomes of Apixaban Versus Warfarin in Patients With Atrial Fibrillation. <i>Circulation</i> , 2019, 139, 2301-2303.	1.6	2
58	Intensive recreational athletes in the prospective multinational ICD Sports Safety Registry: Results from the European cohort. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 764-775.	0.8	32
59	Canâ€™t get out of this world alive. <i>Europace</i> , 2019, 21, 995-996.	0.7	0
60	Competitive athletes with implantable cardioverterâ€‘defibrillatorsâ€‘How to program? Data from the Implantable Cardioverterâ€‘Defibrillator Sports Registry. <i>Heart Rhythm</i> , 2019, 16, 581-587.	0.3	27
61	Frailty and multi-morbidities should not govern oral anticoagulation therapy prescribing for patients with atrial fibrillation. <i>American Heart Journal</i> , 2019, 208, 120-122.	1.2	5
62	Acute Water Ingestion as a Treatment for Postural Orthostatic Tachycardia Syndrome. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2019, 10, 3541-3544.	0.2	2
63	The Mysterious Case of an Athletic Woman with Recurrent Syncope and a â€‘Normalâ€‘Heart. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2019, 10, 3744-3749.	0.2	0
64	Outcomes in syncope research: it is time to standardize. <i>Internal and Emergency Medicine</i> , 2018, 13, 589-591.	1.0	1
65	Strokeâ€‘prevention strategies in North American patients with atrial fibrillation: The GLORIAâ€‘AF registry program. <i>Clinical Cardiology</i> , 2018, 41, 744-751.	0.7	19
66	Bundle Branch Reentry Tachycardia. , 2018, , 799-813.		0
67	Pacing for Vasovagal Syncope. <i>Arrhythmia and Electrophysiology Review</i> , 2018, 7, 95.	1.3	22
68	82 The Impact of Stroke Prophylaxis on Clinical Outcomes After US Emergency Department Diagnosis and Discharge for Atrial Fibrillation. <i>Annals of Emergency Medicine</i> , 2018, 72, S36.	0.3	0
69	Safety of Sports for Young Patients With Implantable Cardioverter-Defibrillators. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e006305.	2.1	39
70	The Very Little Ladyâ€‘Who Wasn't So Little: Steve Olshansky,* â€‘The Otterâ€‘ PACE - Pacing and Clinical Electrophysiology, 2018, 41, 1268-1268.	0.5	0
71	Stroke Prophylaxis After a New Emergency Department Diagnosis of Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 471-472.	1.2	3
72	Development of Cardiac Implantable Electrical Devices. , 2018, , 1-12.		0

#	ARTICLE	IF	CITATIONS
73	Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC (Atrial Fibrillation Better Care) Pathway. American Journal of Medicine, 2018, 131, 1359-1366.e6.	0.6	129
74	Addition of minute ventilation to rate-response pacing improves heart rate score more than accelerometer alone. Heart Rhythm, 2018, 15, 1730-1735.	0.3	6
75	Highlights from Heart Rhythm 2018: Late-breaking Clinical Trial Considerations. Journal of Innovations in Cardiac Rhythm Management, 2018, 10, 3321-3323.	0.2	0
76	A Case of Postablation Pericardial Effusion. Journal of Innovations in Cardiac Rhythm Management, 2018, 9, 3365-3368.	0.2	1
77	Evaluation and Management of Syncope: Comparing the Guidelines of the American College of Cardiology/American Heart Association/Heart Rhythm Society and the European Society of Cardiology. Journal of Innovations in Cardiac Rhythm Management, 2018, 9, 3457-3463.	0.2	1
78	Syncope: Outcomes and Conditions Associated with Hospitalization. American Journal of Medicine, 2017, 130, 699-706.e6.	0.6	24
79	Longitudinal changes in quality of life following ICD implant and the impact of age, gender, and ICD shocks: observations from the INTRINSIC RV trial. Journal of Interventional Cardiac Electrophysiology, 2017, 48, 291-298.	0.6	22
80	2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope. Heart Rhythm, 2017, 14, e155-e217.	0.3	163
81	2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: Executive Summary. Journal of the American College of Cardiology, 2017, 70, 620-663.	1.2	131
82	2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope. Journal of the American College of Cardiology, 2017, 70, e39-e110.	1.2	231
83	2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: Executive summary. Heart Rhythm, 2017, 14, e218-e254.	0.3	27
84	2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation, 2017, 136, e25-e59.	1.6	215
85	2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation, 2017, 136, e60-e122.	1.6	189
86	A Device Histogram-Based Simple Predictor of Mortality Risk in ICD and CRT-D Patients: The Heart Rate Score. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 333-343.	0.5	16
87	2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. Heart Rhythm, 2017, 14, e55-e96.	0.3	204
88	2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. , 2017, 22, e12447.		52
89	PREDICTORS OF ANTICOAGULANT PRESCRIPTION IN PATIENTS WITH ATRIAL FIBRILLATION IN NORTH AMERICA: THE GLORIA-AF REGISTRY. Journal of the American College of Cardiology, 2017, 69, 413.	1.2	1
90	MY APPROACH to the patient with supraventricular tachycardia â. Trends in Cardiovascular Medicine, 2017, 27, 378-379.	2.3	0

#	ARTICLE	IF	CITATIONS
91	Cardiac implantable electronic device infections: Who is at greatest risk?. Heart Rhythm, 2017, 14, 839-845.	0.3	70
92	Vasovagal Syncope. Journal of the American College of Cardiology, 2017, 70, 1729-1731.	1.2	6
93	Systolic Blood Pressure Visit-to-Visit Variability and Major Adverse Outcomes in Atrial Fibrillation. Hypertension, 2017, 70, 949-958.	1.3	28
94	106 Stroke Prophylaxis and 30-Day Clinical Outcomes After US Emergency Department Diagnosis and Discharge for Atrial Fibrillation. Annals of Emergency Medicine, 2017, 70, S43.	0.3	0
95	Effect of Ablation for Atrial Fibrillation on Heart Failure Readmission Rates. American Journal of Cardiology, 2017, 120, 1572-1577.	0.7	15
96	Does First Degree AV Block Have Importance in Patients Considered for Cardiac Resynchronization Therapy?. JACC: Clinical Electrophysiology, 2017, 3, 827-829.	1.3	2
97	Tachycardia-induced ventricular dysfunction jigsaw: do all pieces now fit?. Acta Physiologica, 2017, 219, 702-703.	1.8	1
98	Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulaci3n Card3aca y. Europace, 2017, 19, 1757-1758.	0.7	107
99	How to Perform Pacemaker Troubleshooting. , 2017, , 173-186.		0
100	Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Es. Thrombosis and Haemostasis, 2017, 117, 2215-2236.	1.8	41
101	Safety of Sports for Athletes With Implantable Cardioverter-Defibrillators. Circulation, 2017, 135, 2310-2312.	1.6	107
102	Implantable Cardiac Monitors: Evolution Through Disruption. Journal of Innovations in Cardiac Rhythm Management, 2017, 8, 2824-2834.	0.2	4
103	Electrical Stimulation of the Vagus Nerve for Chronic Heart Failure: Is It Time to Pull the Plug?. Journal of Cardiac Failure, 2016, 22, 643-645.	0.7	4
104	Survival After Rate-Responsive Programming in Patients With Cardiac Resynchronization Therapy-Defibrillator Implants Is Associated With a Novel Parameter. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	2.1	23
105	Mortality After Atrioventricular Nodal Radiofrequency Catheter Ablation With Permanent Ventricular Pacing in Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	2.1	21
106	Rate control in atrial fibrillation. Lancet, The, 2016, 388, 818-828.	6.3	140
107	Automatic external defibrillator“only resuscitation in cardiac arrest? The approach may be shocking!. American Heart Journal, 2016, 172, 182-184.	1.2	2
108	Relation of female sex to left atrial diameter and cardiovascular death in atrial fibrillation: The AFFIRM Trial. International Journal of Cardiology, 2016, 207, 258-263.	0.8	43

#	ARTICLE	IF	CITATIONS
109	On the Road Again After Vasovagal Syncope?. JACC: Clinical Electrophysiology, 2016, 2, 209-211.	1.3	0
110	Cardiac Resynchronization Therapy May Be Antiarrhythmic Particularly in Responders. JACC: Clinical Electrophysiology, 2016, 2, 307-316.	1.3	11
111	Vagus nerve modulation of inflammation: Cardiovascular implications. Trends in Cardiovascular Medicine, 2016, 26, 1-11.	2.3	36
112	Atrial electrograms improve the accuracy of tachycardia interpretation from ICD and pacemaker recordings: The RATE Registry. Heart Rhythm, 2016, 13, 1475-1480.	0.3	10
113	Practical Management Guide for Clinicians Who Treat Patients with Amiodarone. American Journal of Medicine, 2016, 129, 468-475.	0.6	86
114	Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. Clinical Research in Cardiology, 2016, 105, 412-420.	1.5	78
115	2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia. Heart Rhythm, 2016, 13, e136-e221.	0.3	84
116	2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. Journal of the American College of Cardiology, 2016, 67, e27-e115.	1.2	325
117	2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. Circulation, 2016, 133, e506-74.	1.6	320
118	2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary. Circulation, 2016, 133, e471-505.	1.6	96
119	2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: Executive summary. Heart Rhythm, 2016, 13, e92-e135.	0.3	23
120	2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary. Journal of the American College of Cardiology, 2016, 67, 1575-1623.	1.2	86
121	Conventional management of inappropriate sinus tachycardia. Journal of Interventional Cardiac Electrophysiology, 2016, 46, 43-45.	0.6	4
122	Syncopal clinical management in the emergency department: a consensus from the first international workshop on syncope risk stratification in the emergency department. European Heart Journal, 2016, 37, 1493-1498.	1.0	96
123	An unusual ICD shock: What is the mechanism?. HeartRhythm Case Reports, 2015, 1, 498-502.	0.2	0
124	The SAME-TT2R2 score and quality of anticoagulation in AF: Can we predict which patient benefits from anticoagulation?. Thrombosis and Haemostasis, 2015, 114, 657-659.	1.8	22
125	Digoxin Use to Control Ventricular Rate in Patients with Atrial Fibrillation and Heart Failure Is Not Associated with Increased Mortality. Cardiology Research and Practice, 2015, 2015, 1-10.	0.5	17
126	Management of tachycardia. F1000prime Reports, 2015, 7, 60.	5.9	26



#	ARTICLE	IF	CITATIONS
127	2015 Heart Rhythm Society Expert Consensus Statement on the Diagnosis and Treatment of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia, and Vasovagal Syncope. <i>Heart Rhythm</i> , 2015, 12, e41-e63.	0.3	694
128	Time-dependent risk reduction of ventricular tachyarrhythmias in cardiac resynchronization therapy patients: a MADIT-RIT sub-study. <i>Europace</i> , 2015, 17, 1085.1-1091.	0.7	16
129	Warning: Acute pancreatitis is associated with slightly higher current amiodarone use. <i>Heart Rhythm</i> , 2015, 12, 167-168.	0.3	1
130	The non-vitamin K oral anticoagulants (NOACs): Have all questions been answered?. <i>Trends in Cardiovascular Medicine</i> , 2015, 25, 337-339.	2.3	0
131	Syncope in Patients with Organic Heart Disease. <i>Cardiology Clinics</i> , 2015, 33, 449-463.	0.9	5
132	Arrhythmia-Induced Cardiomyopathies. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1714-1728.	1.2	277
133	Meta-Analysis of the Relation of Ventricular Arrhythmias to All-Cause Mortality After Implantation of a Left Ventricular Assist Device. <i>American Journal of Cardiology</i> , 2015, 116, 1385-1390.	0.7	52
134	Characterization and predictors of first and subsequent inappropriate ICD therapy by heart rate ranges: Result of the MADIT-RIT efficacy analysis. <i>Heart Rhythm</i> , 2015, 12, 2030-2037.	0.3	10
135	Syncope Unit: rationale and requirement " the European Heart Rhythm Association position statement endorsed by the Heart Rhythm Society. <i>Europace</i> , 2015, 17, 1325-1340.	0.7	98
136	The Parasympathetic Nervous System and Heart Failure: Pathophysiology and Potential Therapeutic Modalities for Heart Failure. , 2015, , 107-128.		1
137	Bundle Branch Reentry Tachycardia. , 2014, , 835-847.		0
138	Response. <i>Chest</i> , 2014, 145, 419-420.	0.4	1
139	Response to Letter Regarding, "PR Interval Identifies Clinical Response in Patients With Non-Left Bundle Branch Block: A Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy Sub-Study" by Kutyla et al. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 1280-1280.	2.1	3
140	Hormone Replacement Therapy and Adverse Outcomes in Women With Atrial Fibrillation. <i>Stroke</i> , 2014, 45, 3076-3079.	1.0	17
141	Do implantable cardioverter defibrillators improve survival in patients with chronic kidney disease at high risk of sudden cardiac death? A meta-analysis of observational studies. <i>Europace</i> , 2014, 16, 55-62.	0.7	30
142	Does change in device detected frequency of non-sustained or diverted episodes serve as a marker for inappropriate shock therapy? Analyses from the INTRINSIC RV and ALTITUDE-REDUCES Trials. <i>Europace</i> , 2014, 16, 668-673.	0.7	1
143	Increased Prevalence of Atrial Fibrillation in the Endurance Athlete: Potential Mechanisms and Sport Specificity. <i>Physician and Sportsmedicine</i> , 2014, 42, 45-51.	1.0	12
144	Endovascular procedures for the treatment of autonomic dysfunction. <i>Clinical Autonomic Research</i> , 2014, 24, 1-2.	1.4	2

#	ARTICLE	IF	CITATIONS
145	Left ventricular geometry and outcomes in patients with atrial fibrillation: The AFFIRM Trial. <i>International Journal of Cardiology</i> , 2014, 170, 303-308.	0.8	36
146	Sports and Exercise Cardiology in the United States. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1461-1472.	1.2	41
147	Mortality Reduction in Relation to Implantable Cardioverter Defibrillator Programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT). <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 785-792.	2.1	101
148	On the Underutilization of Cardiac Resynchronization Therapy. <i>Journal of Cardiac Failure</i> , 2014, 20, 696-705.	0.7	17
149	Neither Too Fast Nor Too Hot. <i>Journal of the American College of Cardiology</i> , 2014, 64, 470-471.	1.2	0
150	PR Interval Identifies Clinical Response in Patients With Nonâ€œLeft Bundle Branch Block. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 645-651.	2.1	98
151	Priorities for Emergency Department Syncope Research. <i>Annals of Emergency Medicine</i> , 2014, 64, 649-655.e2.	0.3	79
152	Response. <i>Chest</i> , 2014, 145, 188-189.	0.4	3
153	Syncope. <i>Cardiology Journal</i> , 2014, 21, 589-590.	0.5	1
154	Are treatments for vasovagal syncope effective? A meta-analysis. <i>International Journal of Cardiology</i> , 2013, 167, 1906-1911.	0.8	35
155	Syncope in Patients with Organic Heart Disease. <i>Cardiac Electrophysiology Clinics</i> , 2013, 5, 495-509.	0.7	2
156	Sudden Death Risk in Syncope: The Role of The Implantable Cardioverter Defibrillator. <i>Progress in Cardiovascular Diseases</i> , 2013, 55, 443-453.	1.6	4
157	The C-CURE Randomized Clinical Trial (Cardiopoietic stem Cell therapy in heart failURE). <i>Journal of the American College of Cardiology</i> , 2013, 62, 2453.	1.2	16
158	Ambulatory ECG Monitoring in Atrial Fibrillation Management. <i>Progress in Cardiovascular Diseases</i> , 2013, 56, 143-152.	1.6	41
159	Does cardiac resynchronization therapy benefit patients with ischemic and non-ischemic cardiomyopathy similarly?. <i>International Journal of Cardiology</i> , 2013, 168, 4378-4380.	0.8	8
160	Inappropriate Sinus Tachycardia. <i>Journal of the American College of Cardiology</i> , 2013, 61, 793-801.	1.2	135
161	Safety of Sports for Athletes With Implantable Cardioverter-Defibrillators. <i>Circulation</i> , 2013, 127, 2021-2030.	1.6	209
162	Influence of Diabetes Mellitus on Inappropriate and Appropriate Implantable Cardioverter-Defibrillator Therapy and Mortality in the Multicenter Automatic Defibrillator Implantation Trialâ€œReduce Inappropriate Therapy (MADIT-RIT) Trial. <i>Circulation</i> , 2013, 128, 694-701.	1.6	25

#	ARTICLE	IF	CITATIONS
163	Do Baseline Diastolic Echocardiographic Parameters Predict Outcome after Resynchronization Therapy? Results from the PROSPECT Trial. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2013, 36, 214-220.	0.5	7
164	Mode of death and factors associated with cardiac and non-cardiac death in the MADIT-RIT trial. <i>European Heart Journal</i> , 2013, 34, P1375-P1375.	1.0	0
165	Factors Affecting Quality of Anticoagulation Control Among Patients With Atrial Fibrillation on Warfarin. <i>Chest</i> , 2013, 144, 1555-1563.	0.4	440
166	A Randomized, Placebo-Controlled Trial of Omega-3 Fatty Acids for Inhibition of Supraventricular Arrhythmias After Cardiac Surgery: The FISH Trial. <i>Journal of the American Heart Association</i> , 2012, 1, e000547.	1.6	54
167	Left ventricular geometry and outcome in patients with atrial fibrillation: insights from the affirm trial. <i>Heart</i> , 2012, 98, A32.3-A33.	1.2	0
168	Factors affecting quality of warfarin anticoagulation in patients with atrial fibrillation: insights from affirm. <i>Heart</i> , 2012, 98, A32.2-A32.	1.2	1
169	Multicenter Automatic Defibrillator Implantation Trial: Reduce Inappropriate Therapy (MADIT-RIT): Background, Rationale, and Clinical Protocol. <i>Annals of Noninvasive Electrocardiology</i> , 2012, 17, 176-185.	0.5	36
170	Reduction in Inappropriate Therapy and Mortality through ICD Programming. <i>New England Journal of Medicine</i> , 2012, 367, 2275-2283.	13.9	1,186
171	Does cardiac resynchronization therapy provide unrecognized benefit in patients with prolonged PR intervals? The impact of restoring atrioventricular synchrony: An analysis from the COMPANION Trial. <i>Heart Rhythm</i> , 2012, 9, 34-39.	0.3	63
172	Using omega-3 fatty acids to treat persistent atrial fibrillation: Time to fish or cut bait?. <i>Heart Rhythm</i> , 2012, 9, 492-493.	0.3	2
173	HRS/ACCF Expert Consensus Statement on Pacemaker Device and Mode Selection. <i>Heart Rhythm</i> , 2012, 9, 1344-1365.	0.3	60
174	Arrhythmia rate distribution and tachyarrhythmia therapy in an ICD population: Results from the INTRINSIC RV trial. <i>Heart Rhythm</i> , 2012, 9, 351-358.	0.3	20
175	HRS/ACCF Expert Consensus Statement on Pacemaker Device and Mode Selection. <i>Journal of the American College of Cardiology</i> , 2012, 60, 682-703.	1.2	62
176	Relation of Gender-Specific Risk of Ischemic Stroke in Patients With Atrial Fibrillation to Differences in Warfarin Anticoagulation Control (from AFFIRM). <i>American Journal of Cardiology</i> , 2012, 110, 1799-1802.	0.7	85
177	The Road Ends in Detroit. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2012, 35, 754-756.	0.5	0
178	The Editor's Roundtable: Medical Management of Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2012, 109, 563-569.	0.7	2
179	Is a Dual-Chamber ICD Always Better in Patients Requiring an ICD?. <i>Cardiac Electrophysiology Clinics</i> , 2011, 3, 577-592.	0.7	0
180	Electrocardiographic imaging: Back to the drawing board?. <i>Heart Rhythm</i> , 2011, 8, 700-701.	0.3	4

#	ARTICLE	IF	CITATIONS
181	Prescription omega-3 fatty acids did not prevent recurrent, symptomatic, paroxysmal or persistent atrial fibrillation. <i>Annals of Internal Medicine</i> , 2011, 154, JC5.	2.0	1
182	Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 186-196.	1.1	56
183	OptiVol Fluid Index: Does an Association With Ventricular Arrhythmias Hold Water?. <i>Journal of Cardiovascular Electrophysiology</i> , 2011, 22, 300-301.	0.8	2
184	The Editor's Roundtable: Implantable Cardioverter-Defibrillators in Primary Prevention of Sudden Cardiac Death and Disparity-Related Barriers to Implementation. <i>American Journal of Cardiology</i> , 2011, 107, 583-590.	0.7	1
185	Inflammatory cytokines and nitric oxide in heart failure and potential modulation by vagus nerve stimulation. <i>Heart Failure Reviews</i> , 2011, 16, 137-145.	1.7	54
186	Older Persons with Diabetes Receive Fewer Inappropriate ICD Shocks: Results from the INTRINSIC RV Trial. <i>Journal of Cardiovascular Translational Research</i> , 2011, 4, 27-34.	1.1	5
187	Diagnosis of Arrhythmias with Non-invasive Tools. , 2011, , 89-122.		0
188	Electrophysiological Approach to Syncope and Near-Syncope in the Athlete. , 2011, , 181-212.		1
189	Dronedronarone: evidence supporting its therapeutic use in the treatment of atrial fibrillation. <i>Core Evidence</i> , 2010, 5, 49.	4.7	0
190	Response to Letters Regarding Article, "Heart Rate Predicts Outcomes in an Implantable Cardioverter-Defibrillator Population". <i>Circulation</i> , 2010, 121, .	1.6	0
191	In permanent atrial fibrillation, lenient rate control is not inferior to strict rate control for preventing cardiovascular morbidity and mortality. <i>Evidence-Based Medicine</i> , 2010, 15, 147-148.	0.6	0
192	Delayed maximal response to left cardiac sympathectomy for catecholaminergic polymorphic ventricular tachycardia. <i>Europace</i> , 2010, 12, 1035-1039.	0.7	18
193	Carotid sinus hypersensitivity: disease state or clinical sign of ageing? The need for hard endpoints. <i>Europace</i> , 2010, 12, 1516-1517.	0.7	2
194	The year in arrhythmias"2009 Part II. <i>Heart Rhythm</i> , 2010, 7, 538-548.	0.3	0
195	The year in arrhythmias"2009: Part I. <i>Heart Rhythm</i> , 2010, 7, 417-426.	0.3	3
196	Heart Rate Predicts Outcomes in an Implantable Cardioverter-Defibrillator Population. <i>Circulation</i> , 2009, 120, 2040-2045.	1.6	57
197	Not so innocent bystander(s). <i>Europace</i> , 2009, 11, 1230-1234.	0.7	1
198	Electrophysiological device therapy (implantable defibrillators) in older adults. <i>Current Cardiovascular Risk Reports</i> , 2009, 3, 347-354.	0.8	0

#	ARTICLE	IF	CITATIONS
199	Tachycardia-mediated cardiomyopathy: Recognition and management. <i>Current Heart Failure Reports</i> , 2009, 6, 257-264.	1.3	37
200	The Dual Role of Implantable Loop Recorder in Patients with Potentially Arrhythmic Symptoms: A Retrospective Single-Center Study. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009, 32, 908-912.	0.5	14
201	Influence of Left Ventricular Lead Location on Outcomes in the COMPANION Study. <i>Journal of Cardiovascular Electrophysiology</i> , 2009, 20, 764-768.	0.8	129
202	Implantable Cardioverter Defibrillators: Do Women Fare Worse Than Men? Gender Comparison in the INTRINSIC RV Trial. <i>Journal of Cardiovascular Electrophysiology</i> , 2009, 20, 973-978.	0.8	31
203	Correlation of Noninvasive Electrocardiography with Invasive Electrophysiology in Syncope of Unknown Origin: Implications from a Large Syncope Database. <i>Annals of Noninvasive Electrocardiology</i> , 2009, 14, 119-127.	0.5	27
204	Bolus isoproterenol infusions provide a reliable method for assessing interoceptive awareness. <i>International Journal of Psychophysiology</i> , 2009, 72, 34-45.	0.5	120
205	Guidelines for the diagnosis and management of syncope (version 2009): The Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2009, 30, 2631-2671.	1.0	1,784
206	Newly detected atrial fibrillation in patients with an implantable cardioverter-defibrillator is a strong risk marker of increased mortality. <i>Heart Rhythm</i> , 2009, 6, 2-8.	0.3	64
207	Update on medical management of atrial fibrillation in the modern era. <i>Heart Rhythm</i> , 2009, 6, S17-S22.	0.3	9
208	Treatment of PVCs post-myocardial infarction: Will we get fooled again?. <i>Heart Rhythm</i> , 2009, 6, 1550-1551.	0.3	3
209	Advances in the management of atrial fibrillation in congestive heart failure. <i>F1000 Medicine Reports</i> , 2009, 1, .	2.9	1
210	Resting sinus heart rate and first degree av block: modifiable risk predictors or epiphenomena?. <i>Indian Pacing and Electrophysiology Journal</i> , 2009, 9, 334-41.	0.3	3
211	The Understudy: On Being a Doctor. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2008, 31, 1640-1640.	0.5	0
212	What's So Inappropriate About Sinus Tachycardia?. <i>Journal of Cardiovascular Electrophysiology</i> , 2008, 19, 977-978.	0.8	8
213	Thorough QT Study With Recommended and Supratherapeutic Doses of Tolterodine. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 231-232.	2.3	4
214	Syncope Predicts the Outcome of Cardiomyopathy Patients. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1277-1282.	1.2	106
215	Antiarrhythmic Effects of Statins in Heart Failure. <i>Heart Failure Clinics</i> , 2008, 4, 187-200.	1.0	2
216	Slower Heart Rates for Healthy Hearts. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2008, 1, 321-323.	2.1	9

#	ARTICLE	IF	CITATIONS
217	Parasympathetic Nervous System and Heart Failure. <i>Circulation</i> , 2008, 118, 863-871.	1.6	377
218	Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-controlled, Double-blind, Crossover Study With Tolterodine and Darifenacin in Healthy Participants $\geq$ 50 Years. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2008, 13, 241-251.	1.0	63
219	High defibrillation energy requirements are encountered rarely with modern dual-chamber implantable cardioverter-defibrillator systems. <i>Europace</i> , 2008, 10, 347-350.	0.7	28
220	Ibutilide revisited: stronger and safer than ever. <i>Europace</i> , 2008, 11, 9-10.	0.7	4
221	Indications for Implantable Cardioverter Defibrillators. , 2008, , 495-546.		0
222	Can lipid-lowering medication reduce the prevalence of atrial fibrillation in patients with left ventricular dysfunction?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, 16-17.	3.3	2
223	Is Dual-Chamber Programming Inferior to Single-Chamber Programming in an Implantable Cardioverter-Defibrillator?. <i>Circulation</i> , 2007, 115, 9-16.	1.6	159
224	Sex Differences in the Relationship Between Amiodarone Use and the Need for Permanent Pacing in Patients With Atrial Fibrillation. <i>Archives of Internal Medicine</i> , 2007, 167, 1648.	4.3	33
225	Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: Mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). <i>American Heart Journal</i> , 2007, 153, 573-578.	1.2	81
226	Where patients with mild to moderate heart failure die: Results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). <i>American Heart Journal</i> , 2007, 153, 1089-1094.	1.2	27
227	Arrhythmias in tako-tsubo syndrome—Benign or malignant?. <i>International Journal of Cardiology</i> , 2007, 114, 141-144.	0.8	31
228	Eliminating right ventricular pacing may not be best for patients requiring implantable cardioverter-defibrillators. <i>Heart Rhythm</i> , 2007, 4, 886-891.	0.3	40
229	A Practical Guide for Clinicians Who Treat Patients with Amiodarone: 2007. <i>Heart Rhythm</i> , 2007, 4, 1250-1259.	0.3	220
230	Placebo and Nocebo in Cardiovascular Health. <i>Journal of the American College of Cardiology</i> , 2007, 49, 415-421.	1.2	76
231	Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations. <i>BJU International</i> , 2007, 100, 1007-1014.	1.3	27
232	Is the approach to atrial fibrillation ablation becoming more complex and fractionated?. <i>Heart Rhythm</i> , 2006, 3, 35-36.	0.3	3
233	Reduction in Ventricular Tachyarrhythmias With Statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. <i>Journal of the American College of Cardiology</i> , 2006, 47, 769-773.	1.2	169
234	The Association between Right Ventricular Pacing and Use of the AV Search Hysteresis Algorithm in Patients with Implantable Cardioverter Defibrillators: Analysis of a Large Population. <i>Journal of Cardiac Failure</i> , 2006, 12, S63.	0.7	0

#	ARTICLE	IF	CITATIONS
235	Are We Overestimating Percentage of Right Ventricular Pacing in Patients with Implantable Cardioverter Defibrillators?. <i>Journal of Cardiac Failure</i> , 2006, 12, S68.	0.7	0
236	Reduction of Right Ventricular Pacing in Patients with Dual-Chamber ICDs. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2006, 29, 237-243.	0.5	33
237	Fast-Track Training of Nonelectrophysiologists to Implant Defibrillators: Is It Needed?. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2006, 29, 627-631.	0.5	3
238	Safety of Sports Participation in Patients with Implantable Cardioverter Defibrillators: A Survey of Heart Rhythm Society Members. <i>Journal of Cardiovascular Electrophysiology</i> , 2006, 17, 11-15.	0.8	111
239	Patterns and Predictors of Warfarin Use in Patients With New-Onset Atrial Fibrillation from the FRACTAL Registry. <i>American Journal of Cardiology</i> , 2006, 97, 538-543.	0.7	102
240	Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. <i>Europace</i> , 2006, 8, 935-942.	0.7	141
241	Inhibition of Unnecessary RV Pacing with AV Search Hysteresis in ICDs (INTRINSIC RV):: Design and Clinical Protocol. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2005, 28, 62-66.	0.5	31
242	Use of amiodarone for atrial fibrillation in patients with preexisting pulmonary disease in the AFFIRM study. <i>American Journal of Cardiology</i> , 2005, 95, 404-405.	0.7	39
243	Interrelationships Between the Autonomic Nervous System and Atrial Fibrillation. <i>Progress in Cardiovascular Diseases</i> , 2005, 48, 57-78.	1.6	80
244	Rate versus rhythm control strategies for AF. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2005, 7, 371-381.	0.4	1
245	Anticoagulation: New challenges, old drugs. <i>Current Cardiology Reports</i> , 2005, 7, 359-361.	1.3	0
246	Acute anticoagulation adjustment in patients with atrial fibrillation at risk for stroke: approaches, strategies, risks and benefits. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 571-590.	0.6	2
247	Temporary biventricular pacing in a patient with subacute myocardial infarction, cardiogenic shock, and third-degree atrioventricular block. <i>Heart Rhythm</i> , 2005, 2, 112.	0.3	7
248	Addendum to the clinical competency statement: training pathways for implantation of cardioverter defibrillators and cardiac resynchronization devices. <i>Heart Rhythm</i> , 2005, 2, 1161-1163.	0.3	19
249	Electrophysiologists Prefer Dual-Chamber Implantable Cardioverter Defibrillator Programming Even When Right Ventricular Pacing Is Likely. <i>Journal of Cardiac Failure</i> , 2005, 11, S147.	0.7	1
250	Task Force 9: Drugs and performance-enhancing substances. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1368-1369.	1.2	7
251	Are Transthoracic Echocardiographic Parameters Associated With Atrial Fibrillation Recurrence or Stroke?. <i>Journal of the American College of Cardiology</i> , 2005, 45, 2026-2033.	1.2	142
252	Integrating Complementary Medicine Into Cardiovascular Medicine. <i>Journal of the American College of Cardiology</i> , 2005, 46, 184-221.	1.2	126

#	ARTICLE	IF	CITATIONS
253	Analysis of Cause-Specific Mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. <i>Circulation</i> , 2004, 109, 1973-1980.	1.6	215
254	Heart Failure and Sudden Death in Patients With Tachycardia-Induced Cardiomyopathy and Recurrent Tachycardia. <i>Circulation</i> , 2004, 110, 247-252.	1.6	326
255	Cardioversion of atrial tachyarrhythmias: anticoagulation to reduce thromboembolic complications. <i>Progress in Cardiovascular Diseases</i> , 2004, 46, 487-505.	1.6	3
256	The Impact of Atrial Prevention and Termination Therapies on Atrial Tachyarrhythmia Burden in Patients Receiving a Dual-Chamber Defibrillator for Ventricular Arrhythmias. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2004, 10, 103-110.	0.6	20
257	Electrophysiological Characterization of Cardiac Veins in Humans. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2004, 10, 241-247.	0.6	8
258	Rate control in atrial fibrillation: what approach is best?. <i>Current Cardiology Reports</i> , 2004, 6, 351-353.	1.3	0
259	Advances in Atrial Flutter Mapping: What Goes Around Comes Around. <i>Journal of Cardiovascular Electrophysiology</i> , 2004, 15, 415-417.	0.8	4
260	The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. <i>Journal of the American College of Cardiology</i> , 2004, 43, 1201-1208.	1.2	378
261	Optimization of right ventricular pacing among patients with dual-chamber implantable cardioverter defibrillators. <i>Journal of Cardiac Failure</i> , 2004, 10, S66.	0.7	0
262	Variation in the utilization of antiarrhythmic drugs in patients with new-onset atrial fibrillation. <i>American Journal of Cardiology</i> , 2003, 91, 81-83.	0.7	34
263	Irregular Atrial Activation During Atrioventricular Nodal Reentrant Tachycardia. <i>Journal of Cardiovascular Electrophysiology</i> , 2003, 14, 309-313.	0.8	15
264	Inadvertent Positioning of Pacemaker Leads in the Pericardium. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2003, 26, 2039-2041.	0.5	3
265	Etiologic Considerations in the Patient With Syncope and an Apparently Normal Heart. <i>Archives of Internal Medicine</i> , 2003, 163, 151.	4.3	47
266	Outpatient cardioversion of atrial arrhythmias: Efficacy, safety, and costs. <i>American Heart Journal</i> , 2003, 145, 233-238.	1.2	73
267	Retroactive prayer: a preposterous hypothesis?. <i>BMJ: British Medical Journal</i> , 2003, 327, 1465-1468.	2.4	13
268	Early versus late atrial fibrillation after atrial flutter ablation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2002, 6, 173-180.	0.6	17
269	Baseline characteristics of patients with atrial fibrillation: The AFFIRM Study. <i>American Heart Journal</i> , 2002, 143, 991-1001.	1.2	157
270	Unusual Response to Atrial Extrastimulus Testing. <i>Journal of Cardiovascular Electrophysiology</i> , 2002, 13, 200-200.	0.8	1



#	ARTICLE	IF	CITATIONS
271	Implantable Defibrillator Use for De Novo Ventricular Tachyarrhythmias Encountered After Cardiac Surgery. PACE - Pacing and Clinical Electrophysiology, 2002, 25, 951-956.	0.5	12
272	Alternative medicine--boom or bust?. Journal of Interventional Cardiac Electrophysiology, 2002, 6, 170-173.	0.9	3
273	APOPTOSIS IN THE GENESIS OF CARDIAC RHYTHM DISORDERS. Cardiology Clinics, 2001, 19, 155-163.	0.9	32
274	Syncope. Current Treatment Options in Cardiovascular Medicine, 2001, 3, 299-310.	0.4	0
275	Implantable Cardioverter Defibrillator Practices and Costs at an Academic Medical Center. Journal of Cardiovascular Electrophysiology, 2001, 12, 162-166.	0.8	5
276	For Whom Does the Bell Toll?. Journal of Cardiovascular Electrophysiology, 2001, 12, 1002-1003.	0.8	4
277	Report of the NASPE Policy Conference on Arrhythmias and the Athlete. Journal of Cardiovascular Electrophysiology, 2001, 12, 1208-1219.	0.8	94
278	Patient-Heal Thyself? Electrophysiology Meets Alternative Medicine. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 403-405.	0.5	7
279	Apparent bidirectional conduction block following radiofrequency catheter ablation of typical atrial flutter. Journal of Interventional Cardiac Electrophysiology, 2001, 5, 109-118.	0.6	1
280	Environmental and Drug Effects on Patients With Pacemakers and Implantable Cardioverter/Defibrillators. Archives of Internal Medicine, 2001, 161, 649.	4.3	76
281	Ventricular tachycardia with QRS configuration similar to that in sinus rhythm and a myocardial origin: differential diagnosis with bundle branch reentry. Europace, 2001, 3, 115-123.	0.7	16
282	Syncope Evaluation at a Crossroad. Circulation, 2001, 104, 7-8.	1.6	10
283	The Death of My Father. PACE - Pacing and Clinical Electrophysiology, 2000, 23, 525-526.	0.5	1
284	Request for assistance. American Journal of Cardiology, 2000, 85, 674.	0.7	0
285	Request for assistance. American Journal of Cardiology, 2000, 85, 800.	0.7	0
286	Predictive value of preoperative left ventricular ejection fraction and functional class for mortality and morbidity after high-risk coronary artery bypass grafting. American Journal of Cardiology, 2000, 85, 1489-1491.	0.7	4
287	Request for assistance. American Journal of Cardiology, 2000, 85, 1041.	0.7	0
288	Location of death (in-hospital or out-of-hospital) and type of death (arrhythmic, nonarrhythmic,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7. ventricular tachycardia, or nonfatal cardiac arrest (the ESVEM trial). American Journal of Cardiology, 2000, 86, 846-851.	0.7	7

#	ARTICLE	IF	CITATIONS
289	Implantable cardioverter defibrillator therapy for patients with life-threatening ventricular arrhythmias and severe heart failure. <i>American Journal of Cardiology</i> , 2000, 86, 875-877.	0.7	1
290	Radiofrequency application to the posteroseptal region alters retrograde accessory pathway activation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2000, 4, 283-293.	0.6	2
291	Practical Guidelines for Clinicians Who Treat Patients With Amiodarone. <i>Archives of Internal Medicine</i> , 2000, 160, 1741.	4.3	178
292	A Pepsi Challenge. <i>New England Journal of Medicine</i> , 1999, 340, 2006-2006.	13.9	27
293	Catheter Ablation of Accessory Pathways, Atrioventricular Nodal Reentrant Tachycardia, and the Atrioventricular Junction. <i>Circulation</i> , 1999, 99, 262-270.	1.6	591
294	Atrial flutter. <i>Current Treatment Options in Cardiovascular Medicine</i> , 1999, 1, 167-177.	0.4	0
295	Request for assistance. <i>American Journal of Cardiology</i> , 1999, 84, 1277.	0.7	0
296	Clinical significance of syncope in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) trial. <i>American Heart Journal</i> , 1999, 137, 878-886.	1.2	73
297	A Practical Approach to Atrial Fibrillation. <i>Hospital Practice (1995)</i> , 1999, 34, 61-78.	0.5	2
298	Cardiac arrhythmias and the athlete. <i>Current Opinion in Cardiology</i> , 1999, 14, 24.	0.8	10
299	Atrial Tachycardia Originating from a Single Site with Exit Block Mimicking Atrial Fibrillation Eliminated with Radiofrequency Applications. <i>Journal of Cardiovascular Electrophysiology</i> , 1998, 9, 1100-1108.	0.8	16
300	Amiodarone-Induced Pulmonary Toxicity. <i>New England Journal of Medicine</i> , 1997, 337, 1814-1814.	13.9	4
301	Apparent Failure of a Precordial Magnet and Pacemaker Programmer to Convert a DDD Pacemaker to VOO Mode during the Use of the Electrosurgical Unit. <i>Anesthesiology</i> , 1997, 86, 247-250.	1.3	13
302	Telectronics 330-801 Atrial Lead Extraction via the Subclavian Approach. <i>Annals of Thoracic Surgery</i> , 1997, 64, 175-180.	0.7	6
303	Thromboembolism in Chronic Atrial Flutter: Is the Risk Underestimated?. <i>Journal of the American College of Cardiology</i> , 1997, 30, 1506-1511.	1.2	97
304	Autonomic influences in atrial ischemia: vagally mediated atrial conduction improvement. <i>International Journal of Cardiology</i> , 1997, 61, 157-163.	0.8	4
305	Symptomatic Atrioventricular Block in an Atriofascicular Pathway Inserting into the Left Bundle Branch Without Apparent Atrioventricular Node Function. <i>Journal of Cardiovascular Electrophysiology</i> , 1997, 8, 922-926.	0.8	1
306	Is Syncope the Same Thing as Sudden Death Except that You Wake Up?. <i>Journal of Cardiovascular Electrophysiology</i> , 1997, 8, 1098-1101.	0.8	15

#	ARTICLE	IF	CITATIONS
307	<a href="#">Predictor Reproducibility of Baseline Arrhythmia Induction on Drug Efficacy Predictions and Outcome in the Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) Trial</a> fn1fn1This study was supported in part by Grant RO-1-HL34071 from the National Heart, Lung, and Blood Institute, and Grant M01-RR00064 from the National Center for Research Resources, Bethesda, Maryland; and by Bristol-Myers Squibb Company, Princeton, New Jersey; Knoll Pharmaceutical Company, Whippany, New Jersey; Boehringer- American Journal of Cardiology, 1997, 80, 1448-1452.	0.7	3
308	Reflex vagal control of atrial repolarization. American Journal of Physiology - Heart and Circulatory Physiology, 1996, 271, H870-H875.	1.5	4
309	Current-based transthoracic defibrillation. American Journal of Cardiology, 1996, 78, 1113-1118.	0.7	15
310	Management of Atrial Fibrillation After Coronary Artery Bypass Graft. American Journal of Cardiology, 1996, 78, 27-34.	0.7	94
311	Influence of holter monitor and electrophysiologic study methods and efficacy criteria on the outcome of patients with ventricular tachycardia and ventricular fibrillation in the ESVEM trial. Progress in Cardiovascular Diseases, 1996, 38, 359-370.	1.6	12
312	Dofetilide Versus Quinidine for Atrial Flutter... Journal of Cardiovascular Electrophysiology, 1996, 7, 828-832.	0.8	1
313	Sympathetic influences on electrical and mechanical alternans in the canine heart. Cardiovascular Research, 1996, 32, 854-860.	1.8	1
314	Predictors of Defibrillation Energy Requirements with Nonpicardial Lead Systems. PACE - Pacing and Clinical Electrophysiology, 1995, 18, 253-260.	0.5	25
315	Adenosine-Sensitive Atrial Tachycardia. PACE - Pacing and Clinical Electrophysiology, 1995, 18, 300-306.	0.5	33
316	Significance and Incidence of Concordance of Drug Efficacy Predictions by Holter Monitoring and Electrophysiological Study in the ESVEM Trial. Circulation, 1995, 91, 1988-1995.	1.6	17
317	Scatter Diagram Analysis: A New Technique for Discriminating Ventricular Tachyarrhythmias. PACE - Pacing and Clinical Electrophysiology, 1994, 17, 1267-1275.	0.5	21
318	The Clinical Significance of Nonsustained Ventricular Tachycardia: Current Perspectives. PACE - Pacing and Clinical Electrophysiology, 1994, 17, 637-664.	0.5	24
319	Coronary Artery Bypass in Patients with Previously Placed Implantable Defibrillators. PACE - Pacing and Clinical Electrophysiology, 1993, 16, 2087-2091.	0.5	0
320	Autoregressive modeling of epicardial electrograms during ventricular fibrillation. IEEE Transactions on Biomedical Engineering, 1993, 40, 379-386.	2.5	6
321	Nonsustained ventricular tachycardia and other high-risk predictors following myocardial infarction: Implications for prophylactic automatic implantable cardioverter-defibrillator use. Progress in Cardiovascular Diseases, 1993, 36, 179-194.	1.6	12
322	Use of multiple patches during implantation of epicardial defibrillator systems. American Journal of Cardiology, 1993, 71, 68-71.	0.7	11
323	Effectiveness of radiofrequency catheter ablation for treatment of atrial tachycardia. American Journal of Cardiology, 1993, 72, 787-793.	0.7	64
324	Efficacy and Adverse Effects of Moracizine for Ventricular Tachycardia. Drug Investigation, 1993, 6, 119-126.	0.6	1

#	ARTICLE	IF	CITATIONS
325	Characterization of double potentials during ventricular tachycardia. Studies during transient entrainment.. Circulation, 1993, 87, 373-381.	1.6	27
326	Adenosine-sensitive ventricular tachycardia. Clinical characteristics and response to catheter ablation.. Circulation, 1993, 87, 126-134.	1.6	199
327	Asymptomatic Nonsustained Ventricular Arrhythmias. Hospital Practice (1995), 1993, 28, 129-144.	0.5	2
328	Nonthoracotomy lead system for implantable defibrillator. Journal of Thoracic and Cardiovascular Surgery, 1993, 106, 1040-1047.	0.4	10
329	Ventricular tachycardia rate and morphology determine energy and current requirements for transthoracic cardioversion.. Circulation, 1992, 85, 158-163.	1.6	55
330	Various Electrocardiographic and Electrophysiologic Presentations of Normal and Abnormal Sinus Node. Journal of Cardiovascular Electrophysiology, 1992, 3, 187-197.	0.8	1
331	Pathological Study of an Explanted Heart Due to Intractable Ventricular Fibrillation. Journal of Cardiovascular Electrophysiology, 1992, 3, 437-441.	0.8	2
332	Atrial Flutter-Update on the Mechanism and Treatment. PACE - Pacing and Clinical Electrophysiology, 1992, 15, 2308-2335.	0.5	49
333	Electrocardiographic body surface potential mapping in the Wolff-Parkinson-White syndrome. Noninvasive determination of the ventricular insertion sites of accessory atrioventricular connections.. Circulation, 1991, 83, 886-901.	1.6	46
334	Control of Refractory Ventricular Tachycardia with Biventricular Assist Devices. PACE - Pacing and Clinical Electrophysiology, 1991, 14, 1432-1434.	0.5	16
335	Surgical Ablation of Ventricular Tachycardia in the Normothermic Heart. Journal of Cardiac Surgery, 1990, 5, 115-121.	0.3	1
336	Electrophysiological testing and nonsustained ventricular tachycardia. Use and limitations in patients with coronary artery disease and impaired ventricular function.. Circulation, 1990, 82, 350-358.	1.6	266
337	Characterization of double potentials in human atrial flutter: Studies during transient entrainment. Journal of the American College of Cardiology, 1990, 15, 833-841.	1.2	147
338	Demonstration of an area of slow conduction in atrial flutter. Journal of the American College of Cardiology, 1990, 16, 1639-1648.	1.2	240
339	Usefulness of isoproterenol in facilitating atrioventricular nodal reentry tachycardia during electrophysiologic testing. American Journal of Cardiology, 1988, 61, 1037-1041.	0.7	29
340	Ventricular tachycardia masquerading as supraventricular tachycardia: A wolf in sheep's clothing. Journal of Electrocardiology, 1988, 21, 377-384.	0.4	19
341	Use of procainamide with rapid atrial pacing for successful conversion of atrial flutter to sinus rhythm. Journal of the American College of Cardiology, 1988, 11, 359-364.	1.2	60
342	A fourth criterion for transient entrainment: the electrogram equivalent of progressive fusion.. Circulation, 1988, 77, 1003-1012.	1.6	137

#	ARTICLE	IF	CITATIONS
343	Energy, current, and success in defibrillation and cardioversion: clinical studies using an automated impedance-based method of energy adjustment.. Circulation, 1988, 77, 1038-1046.	1.6	209
344	Demonstration of the presence of slow conduction during sustained ventricular tachycardia in man: use of transient entrainment of the tachycardia.. Circulation, 1987, 75, 369-378.	1.6	179
345	Use of Implanted Antitachycardia Pacemakers to Treat Paroxysmal Atrial Flutter. Annals of Internal Medicine, 1987, 107, 247.	2.0	8
346	Usefulness of isoproterenol facilitation of ventricular tachycardia induction during extrastimulus testing in predicting effective chronic therapy with beta-adrenergic blockade. American Journal of Cardiology, 1987, 59, 573-577.	0.7	30
347	Echocardiographic Assessment of Schizophrenics and Manics. Journal of Nervous and Mental Disease, 1985, 173, 179-181.	0.5	2
348	Quantitative Echocardiographic Image Texture: Normal Contraction-Related Variability. IEEE Transactions on Medical Imaging, 1985, 4, 185-192.	5.4	23
349	Significance of inducible tachycardia in patients with syncope of unknown origin: A long-term follow-up. Journal of the American College of Cardiology, 1985, 5, 216-223.	1.2	125
350	Variation of left ventricular myocardial gray level on two-dimensional echocardiograms as a result of cardiac contraction.. Circulation, 1984, 70, 972-977.	1.6	69
351	Cardiac Tamponade Caused by Pulmonary Artery Perforation after Central Venous Catheterization. Journal of Parenteral and Enteral Nutrition, 1984, 8, 711-713.	1.3	9
352	N-Acetyl procainamide causing torsades de pointes. American Journal of Cardiology, 1982, 50, 1439-1441.	0.7	99
353	An Approach to Evaluative Research in Social Planning. Social Service Review, 1963, 37, 429-440.	0.3	0
354	Risk Stratificationâ€™ Impact Diagnostic Strategy. , 0, , 24-28.		0
355	Syncope: Overview and Approach to Management. , 0, , 1-46.		14
356	Use of Electrophysiology Studies in Syncope: Practical Aspects for Diagnosis and Treatment. , 0, , 126-158.		1
357	Inherited Arrhythmic and Related Causes of Syncope. , 0, , 207-213.		0
358	Driving and Syncope. , 0, , 322-342.		1
359	Syncope and the Implantable Cardioverter Defibrillator. , 0, , 169-186.		0
360	Arrhythmia-Induced Cardiomyopathy: Mechanisms and Risk Assessment to Guide Management and Follow-Up. Current Cardiovascular Risk Reports, 0, , .	0.8	0